Medtronic PLC (MDT) FinancialsMDTMedtronic PLC

Medtronic PLC (MDT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cardiac Rhythm & Heart Failure, accounting for 21.5% of total sales, equivalent to $2.11B. Other significant revenue streams include Coronary & Peripheral Vascular and Surgical & Endoscopy. Understanding this composition is critical for investors evaluating how MDT navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Medtronic PLC maintains a gross margin of 60.96%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.52%, while the net margin is 15.16%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MDT converts its operational activities into shareholder value.

In the context of the broader market, MDT competes directly with industry leaders such as SYK and ISRG. With a market capitalization of $116.83B, it holds a significant position in the sector. When comparing efficiency, MDT's gross margin of 60.96% stands against SYK's 65.78% and ISRG's 67.78%. Such benchmarking helps identify whether Medtronic PLC is trading at a premium or discount relative to its financial performance.

Medtronic reported its highest annual revenue growth in a decade, with total revenue reaching $9.8 billion in Q4 2026, and a gross margin of 61.97%, reflecting strong operational efficiency.